Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

finals 3124 > CAP > Flashcards

CAP Flashcards

1
Q

what is pneumonia

A

lower respiratory tract infection, of the lung parenchyma

- proliferation of microbial patho in alveolar level

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

mechanism of bacterial entry

A
  1. aspiration of oropharyngeal secretions: bacteria in the oropharyngeal sections enter lungs
  2. inhalation of aerosols: aerosolised droplets that contain bacteria
  3. hematogenous spreading: bacteremia from extra-pulmonary source
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

signs and symptoms of pneumonia

A
  1. cough, chest pains, SOB, hypoxia
  2. fever >38 degree, chills
  3. tachypnea, tachycardia, hypotension
  4. leukocytosis
  5. fatigue, anorexia, Nausea, change in mental status
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

physical examination to diagnose pneumonia

A
  1. diminished breath sounds over the affected are

2. inspiratory crackles during lung expansion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

radiographic findings for pneumonia

A
  1. chest XR or CT

2. new infiltrates or dense consolidations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

lab findings for pneumonia

A

eg. c-reactive protein, procalcitonin
1. non-specific
2. limited discriminatory potential
3. not recommended for routine use to guide antibiotic initiation or discontinuation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

respiratory cultures for pneumonia

A

sputum:
- low yield, frequent contamination by oropharyngeal secretions
- quality sample: > 10 neutrophils % < 25 epithelial cells per low power field

lower respiratory tract samples:

  • less contamination
  • invasive sampling (eg. bronchoalveolar lavage BAL)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

purpose of blood cultures

A

to rule out bacteremia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

urinary antigen test for pneumonia

A
  1. strepococcus pneumonia and legionella pneumophilia
  2. not routinely used due to limitations:
    - indicate exposure to respective patho but remain positive for days-weeks despite tx
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

classification of pneumonia

A
  1. CAP community acquired: <48h after hosp admission
  2. HAP hospital acquires: >=48h after hosp admission
  3. VAP ventilator acquired: >=48h after mechanical ventilation
  4. HCAP healthcare-associated: is obsolete, <48h after hosp admission + (either from (a) nursing home; (b) hospitalised >=48h last 90d; (c) wound care/ IV antibioticss chemo in last 30d; (d) Hemodialysis patients
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

risk factors of CAP

A
  1. age >=65 yo
  2. previous hospitalisation for CAP
  3. smoking
  4. COPD, DM, HF, cancer, immuno
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

prevention of CAP

A
  1. smoking cessation

2. immunisation (influenza & pneumococcal)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

bacterial causes of outpatient CAP

A
  1. streptococcus pneumoniae
  2. haemophilus influenzae
  3. atyps (Mycoplasma pneumoniae, chlamydophila pneumoniae)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

bacterial causes of non severe inpatient CAP

A
  1. streptococcus pneumoniae
  2. haemophilus influenzae
  3. atyps (Mycoplasma pneumoniae, chlamydophila pneumoniae), legionella pneumoniae
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

bacterial causes of severe inpatient CAP

A
  1. streptococcus pneumoniae
  2. haemophilus influenzae
  3. atyps (Mycoplasma pneumoniae, chlamydophila pneumoniae, legionella pneumoniae)
  4. staphylococcus aureus
  5. gram neg bacilli (eg. klebsiella pneumonia, Burkholderia pseudomallei)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

who to stratify risk of CAP

A
  1. pneumonia severity index (STI)

2. CURB-65 score

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

variables in CURB 65 score

A
  1. confusion
  2. urea >7mmol/L
  3. RR >30 bpm
  4. BP <90/60
  5. age >65yo
18
Q

how to score curb 65 score

A

outpatient: 0-1
inpatient: 2
inpatient ICU: >=3

19
Q

major criteria for severe CAP

A

any one:

  1. mechanical ventilation
  2. septic shock requiring vasoactive medications
20
Q

minor criteria for severe CAP

A

any three:

  1. RR >= 30bpm
  2. PaO2/FiO2 <250
  3. multilobar infiltrates
  4. confusion/ disorientation
  5. uremia (urea >7mmol/L)
  6. leukopenia (WBC <4 x10^9/L)
  7. hypothermia (core temp <36degree)
  8. hypotension requiring aggressive fluid resuscitation
21
Q

empiric regimen for generally healthy outpatient

A
  1. PO beta-lactam (amoxi 1g TDS), or

2. PO respi FQ (levo 750mg OD /moxi)

22
Q

empiric regimen for chronic outpatient

A

pt usually have: chronic heart, lung, renal disease, DM, alcoholism, malignancy, asplenia

  1. PO beta lactam (amoxi/clav 625mg TD or 2g BD, or cefuroxime 500mg BD) + PO macrolide (clarithro 500mg BD/azithro 500mg OD)
  2. PO beta lactam (amoxi/clav 625mg TD or 2g BD, or cefuroxime 500mg BD) + PO doxycycline 100mg BD
  3. PO respiratory FQ (levo 750mg OD/moxi)
23
Q

empiric regimen for non severe inpatient

A
  1. IV beta lactam (amoxi/clav 1.2g q8h, or ceftriaxone 1-2g q24h)+ PO macrolide (clarithro 500mg BD/azithro 500mg OD) OR + PO doxycycline 100mg BD
  2. IV beta lactam (pipe/tazo, or ceftazidime 2g q8h) + PO doxycycline 100mg BD (if pseudomonal coverage needed)
  3. IV respiratory FQ (levo 750mg q24h- psuedomonal /moxi)

IV FQ/ BL step down to PO later if possible, macro & doxy given PO

24
Q

empiric regimen for severe inpatient

A
  1. IV beta lactam (amoxi/clav 1.2g q8h, or ceftazidime 2g q8h) + PO macrolide (clarithro 500mg BD/azithro 500mg OD)
  2. IV beta lactam (amoxi/clav 1.2g q8h, or ceftazidime 2g q8h) + PO doxycycline 100mg BD
  3. IV respiratory FQ (levo 750mg q24h- psuedomonal /moxi) + IV ceftazidime 2g q8h

IV FQ/ BL step down to PO later if possible, macro & doxy given PO

25
Q

purpose of ceftazidime in CAP

A

treat Burkholderia pseudomallei

26
Q

purpose of macrolide/ doxycyclines in CAP

A

treat atypical, hence given orally would be usually sufficient since atyps usually not main problem

27
Q

indication for Anaerobic coverage for CAP

A
  1. lung abscess

2. empyema

28
Q

common anerobic species present for CAP

A
  1. bacteriodes fragilis
  2. prevotella sspp.
  3. porphyromonas spp.
  4. fusobacterium spp.
29
Q

add ons for anerobic coverage for CAP

A

inpatient only!!

  1. clindamycin IV/PO
  2. metronidazole IV/PO

(if current regimen dont have amox/clav or moxi)

30
Q

indication for MRSA coverage for CAP

A
  1. prior respiratory isolation of MRSA in last 1 year

2. severe CAP only: hospitalisation and received IV antibiotics within last 90d (locally validated risk factors)

31
Q

add on for MRSA coverage for CAP

A
  1. Vancomycin IV 15mg/kg q8-12h

2. linezolid IV/PO 600mg BD

32
Q

why should daptomycin not be use for MRSA coverage for CAP

A

against airway acquired pneumonia since it is inactivated by alveolar surfactant (not cause it cannot enter the lungs!!)

33
Q

indication for pseudomonal coverage in CAP

A

prior respiratory isolation of pseudomonas aeruginosa in last 1 year

34
Q

add on for pseudomonal coverage in CAP

A

modify regimen to include either:

  1. pipe/tazo IV 4.5g q6-8h
  2. ceftazidime IV 2g q8h
  3. cefepime IV 2g q8h
  4. meropenem IV (avoid unless ESBL)
  5. levo IV/PO
35
Q

why are fluoroquinolones not first line drugs in CAP

A
  1. more severe ADR (tendonitis, tendon rupture, neuropathy, QTc, CNS, hypoglycemia)
  2. development of resistance with overuse (collateral damage)
  3. preserve activity for other gram neg infection since it is the only PO option for pseudomonas aeruginosa
  4. delay diagnosis of TB (suppressive effect)
36
Q

adjunctive corticosteroid therapy

A
  • decrease inflammation in lungs
  • eg. dexamethasone 50mg IV q24h x 4d
  • eg. prednisolone 40mg PO q24h x 7d
  • may decrease length of stay and time to clinical stability
  • an impact is small and likely outweighed by increase in hyperglycemia
  • not routinely recommended
37
Q

efficacy of therapy

A
  • clinical improvements expected in 48-72h (elderly pt / comorbidities may take longer)
  • should not escalate antibiotic therapy in the first 72h (unless culture directed or significant clinical deterioration)
  • radiographic improvement lags behind, up to 4-6w for resolution (repeat only if clinical deterioration)
38
Q

measures regarding empiric coverage of MRSA and/or pseudomonas in CAP

A

may be stopped in 48h if not found on culture and pt improving

39
Q

when to step down for IV tx of CAP

A

all must be achieved

  1. hemodynamically stable
  2. clinically improved/ improving
  3. afebrile >=24h
  4. normally function GIT
  5. able to digest PO meds
40
Q

general benefits of stepping down

A
  1. greater patient comfort and mobility
  2. lower risk of nosocomial acq blood stream infection
  3. decrease phlebitis
  4. decrease preparation and administration time
  5. lower cost
  6. facilitates discharge
41
Q

treatment duration of CAP

A

until clinical stability achieved for at least 5d

  • usually achieve in 48-72h
  • except MRSA/ pseudomonas - 7d
  • except Burkholderia psudomallei: 3-6months (usually culture and do direct tx)
42
Q

what are signs of clinical stability

A
  1. afebrile
  2. able to maintain oral intake
  3. normal vital signs
  4. oxygen saturation
  5. mental status

finals 3124 (7 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions